Brief: MELT PHARMACEUTICALS ANNOUNCES FIRST PATIENT DOSED IN PIVOTAL PHASE 3 PROGRAM OF ITS LEAD PRODUCT CANDIDATE, MELT-300, FOR NEEDLE- AND OPIOID-FREE SEDATION IN PATIENTS UNDERGOING CATARACT SURGERY

Harrow

06/06/2024 13:48

June 6 (Reuters) - Harrow Inc  HROW.O :
    * MELT PHARMACEUTICALS ANNOUNCES FIRST PATIENT DOSED IN
PIVOTAL
PHASE 3 PROGRAM OF ITS LEAD PRODUCT CANDIDATE, MELT-300, FOR
NEEDLE- AND OPIOID-FREE SEDATION IN PATIENTS UNDERGOING CATARACT
SURGERY
    * MELT PHARMACEUTICALS: TOPLINE READOUT EXPECTED IN Q4 2024

Further company coverage:  HROW.O 

 ((Reuters.Briefs@thomsonreuters.com;))